RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 BRAVO Analysis: Laquinimod Reduces Brain Atrophy in Patients with RRMS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 9
OP 9
DO 10.1177/155989771429005
UL http://mdc.sagepub.com/content/14/29/9.1.abstract
AB Laquinimod, an oral immunomodulator under development for the treatment of multiple sclerosis (MS), reduced whole brain atrophy in the ALLEGRO and BRAVO trials [Vollmer T et al. Neurology. 2012]. This study analyzed the effect of laquinimod on the percent volume change in gray and white matter in the phase 3 BRAVO trial [Vollmer T et al. J Neurol. 2014], using a newly developed, longitudinal image analysis technique.